ProPhase Labs, Inc. Secured Long-term Debt, Noncurrent
ProPhase Labs, Inc. (PRPH) had Secured Long-term Debt, Noncurrent of $2.92 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:SecuredLongTermDebt · last filed 2024-11-13
- 2024-09-30: Secured Long-term Debt, Noncurrent $2.92M.
- 2024-06-30: Secured Long-term Debt, Noncurrent $2.93M.
- 2024-03-31: Secured Long-term Debt, Noncurrent $2.93M.
- 2023-12-31: Secured Long-term Debt, Noncurrent $2.92M.
| Period end | Secured Long-term Debt, Noncurrent |
|---|---|
| 2024-09-30 | $2.92M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.93M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.93M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $2.92M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |